Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.69 |
| ▸ | FAAH | O00519 | 13/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | UBE2M | P61081 | 1/20 | 0.56 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10019491 | 0.88 | SMN1; SMN2 (0.63) | SMN1; SMN2NLRP3FAAHMAPTRAB9A | |
| SCHEMBL10051061 | 0.86 | FAAH (0.66) | SMN1; SMN2FAAHMAPTUBE2MDCUN1D1 | |
| SCHEMBL3598939 | 0.81 | FAAH (1.00) | SMN1; SMN2NLRP3FAAH | |
| SCHEMBL3600872 | 0.81 | FAAH (1.00) | FAAHMAPT | |
| SCHEMBL3604165 | 0.79 | FAAH (1.00) | SMN1; SMN2NLRP3FAAHMAPTLMNA | |
| SCHEMBL11145852 | 0.77 | ALDH1A1 (0.88) | SMN1; SMN2NLRP3FAAHMAPTRAB9A | |
| SCHEMBL10282298 | 0.76 | ALDH1A1 (0.72) | SMN1; SMN2NLRP3FAAHMAPTRAB9A | |
| SCHEMBL10051062 | 0.75 | FAAH (0.61) | SMN1; SMN2FAAHMAPTLMNAHTT | |
| SCHEMBL13545508 | 0.74 | FAAH (1.00) | FAAHHTTALDH1A1 | |
| SCHEMBL3595122 | 0.74 | FAAH (1.00) | FAAHHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046224-A1 | TREATMENT OF DIABETES AND METABOLIC SYNDROME | NORDIC BIOSCIENCE A/S (DK) | 2012-02-23 | — | — | US | disclosed |
| WO-2010103045-A1 | TREATMENT OF DIABETES AND METABOLIC SYNDROME | NORDIC BIOSCIENCE A/S (DK) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046224-A1 | TREATMENT OF DIABETES AND METABOLIC SYNDROME | IAPP, GLP1R, CALCA | SMN1; SMN2 1889/4885NLRP3 2984/4885FAAH 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.